“Well, that’s very interesting,” Martoma said. He was silent for a moment, trying to nudge the conversation back toward the bapi trial. “What did you actually see?” Gilman knew that Martoma was asking for details that he was forbidden to share. “I can’t tell you that,” he said. Martoma kept pushing, asking to know what had been observed with bapi. “With multiple antibodies, one might expect to see some nonspecific effects, primarily on joints, so that low back pain or headache or joint pain or other kinds of rheumatological consequences may occur,” Gilman said. “Did they occur?” Martoma asked.
